‘Ozempic drugs’ reduce obesity-associated cancer risk by up to 65%
Only last week, we reported on one of the few negative stories about semaglutide, a member of the class of drugs known as glucagon-like peptide 1 receptor agonists (GLP-1s or GLP-1RAs) that are used to treat diabetes and/or weight loss.Continue Reading… Continue reading ‘Ozempic drugs’ reduce obesity-associated cancer risk by up to 65%